GR

Girija Rani Adiraju

Active Director Director DIN 07861052
DIN 07861052 First appointment Jul 2017 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2017
Shareholding value β€’β€’β€’β€’ Premium profile

About Girija Rani Adiraju

Data last updated:

Girija Rani Adiraju is a Director at Aranox Pharma Private Limited (since 2017). The company operates in Pharma.

DIN 07861052
Primary Designation Director
Industry Pharma
First Appointment 03 Jul 2017
Oldest Company Age 9 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Aranox Pharma Private Limited U24304AP2017PTC106202
Director03 Jul 20172017Active

Board colleagues of Girija Rani Adiraju

NameDINCompanyDesignation
Prem Kumar Bommak01624024Aranox Pharma Private LimitedAdditional Director
Thirumal Rao Pathini07859751Aranox Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Aranox Pharma Private Limited
Premium access

Shareholding and investment profile for Girija Rani Adiraju

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Girija Rani Adiraju

Girija Rani Adiraju currently holds 1 directorship: Aranox Pharma Private Limited (Director, since 03 Jul 2017).

Girija Rani Adiraju was first appointed on 03 Jul 2017 as Director at Aranox Pharma Private Limited.

The current boards of Girija Rani Adiraju's companies include Prem Kumar Bommak (Aranox Pharma Private Limited), Thirumal Rao Pathini (Aranox Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available